Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Paeonia lactiflora-derived extracellular vesicles ameliorate diabetic peripheral neuropathy by modulating chemokine-guided immune trafficking in peripheral nerves.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Lihong, Xia Shiyun, Lin Shuqi, Xie Xiaoyun
Аннотация
AIMS: This study investigated the therapeutic potential of Paeonia lactiflora-derived extracellular vesicles (PRA-EVs) for diabetic peripheral neuropathy (DPN), with a particular focus on their immunomodulatory effects on the CC motif chemokine ligand 21 (CCL21) / CC chemokine receptor type 7 (CCR7) axis.
METHODS: PRA-EVs were isolated and characterized. In vitro, their effects on high glucose (HG)-induced Schwann cell apoptosis, CCL21 expression, and CD8⁺ T-cell migration were assessed. In vivo, therapeutic efficacy was evaluated in an STZ-induced DPN mouse model using behavioral testing, histological analysis, and molecular assays.
RESULTS: PRA-EVs significantly attenuated HG-induced Schwann cell apoptosis and reduced CCL21 expression. In DPN mice, PRA-EVs improved behavioral and structural abnormalities, including neuropathic pain and myelin injury, with efficacy comparable to mecobalamin. Mechanistically, PRA-EVs were associated with downregulation of CCL21/CCR7 signaling and reduced CCR7⁺CD8⁺ T-cell infiltration in sciatic nerves. In addition, PRA-EVs suppressed CD8⁺ T-cell migration to a degree comparable to the CCR7 pathway inhibitor Cosalane. To our knowledge, this is the first study to link PRA-EVs with the amelioration of DPN in association with modulation of the CCL21/CCR7 axis.
CONCLUSION: PRA-EVs ameliorate DPN, at least in part, through modulation of the CCL21/CCR7 axis, thereby attenuating Schwann cell injury and neuroinflammation. These findings support PRA-EVs as a promising multi-target therapeutic strategy for DPN.
METHODS: PRA-EVs were isolated and characterized. In vitro, their effects on high glucose (HG)-induced Schwann cell apoptosis, CCL21 expression, and CD8⁺ T-cell migration were assessed. In vivo, therapeutic efficacy was evaluated in an STZ-induced DPN mouse model using behavioral testing, histological analysis, and molecular assays.
RESULTS: PRA-EVs significantly attenuated HG-induced Schwann cell apoptosis and reduced CCL21 expression. In DPN mice, PRA-EVs improved behavioral and structural abnormalities, including neuropathic pain and myelin injury, with efficacy comparable to mecobalamin. Mechanistically, PRA-EVs were associated with downregulation of CCL21/CCR7 signaling and reduced CCR7⁺CD8⁺ T-cell infiltration in sciatic nerves. In addition, PRA-EVs suppressed CD8⁺ T-cell migration to a degree comparable to the CCR7 pathway inhibitor Cosalane. To our knowledge, this is the first study to link PRA-EVs with the amelioration of DPN in association with modulation of the CCL21/CCR7 axis.
CONCLUSION: PRA-EVs ameliorate DPN, at least in part, through modulation of the CCL21/CCR7 axis, thereby attenuating Schwann cell injury and neuroinflammation. These findings support PRA-EVs as a promising multi-target therapeutic strategy for DPN.